The health-care sectors in both Canada and the U.S. are in the spotlight.
In the U.S., the health-care sectors bettered itself by 0.7%, while in Canada, the increase was 0.5%.
In the case of one Boston-based company, the efforts in the fight against COVID-19 are being rewarded handsomely.
Brite-Strike Technologies Inc. (BSTK.PK) got on the bullhorn Tuesday to say it has developed a low-cost UVC medical device that adds pathogen-killing technology for N95 face masks effective on COVID-19.
N95 masks act as a barrier to help prevent the spread of pathogens in droplets from being exhaled and inhaled but provide no capability to kill pathogens.
"Our patent pending technology," read Tuesday’s news release, "will add this critical component. The micro device can be installed in any N95 or mask with structure like the Under Armour Sportsmask in seconds. The device can also be used in conjunction with hydrogen peroxide and a heat source to decontaminate a single users N95 mask in the field."
BSTK has received Food and Drug Administation approval, allowing it to begin testing.
And, man, how the stock reflected this excitement, catapulting the price six cents, or 304%, to eight cents in the last hour of Tuesday’s session, on 5.9 million shares.
G6 Materials Corp (formerly Graphene 3D Lab), (TSX-Venture:GGG) said its wholly-owned subsidiary, Graphene Laboratories Inc. (GL) has entered into a License and Option Agreement with a U.S.-based clinical-stage biopharmaceutical company. As per the Agreement, Graphene Laboratories will receive a one time cash payment of $220,000 U.S. from its Partner.
In exchange, GL will grant the Partner an exclusive license to use the Intellectual Property for a period of two years. The Partner will also have an option to purchase the Company's IP rights for $1,000,000 U.S. during the License Period. The $220,000 cash payment will not apply toward the option price in the event G6's partner elects to execute its option to purchase.
In Toronto, GGG shares moved higher by half a cent, or 7.7%, to seven cents, on fairly mild volume of 28,000 shares.
